Barclays PLC Purchases 12,657 Shares of Iradimed Corporation (NASDAQ:IRMD)

Barclays PLC increased its position in shares of Iradimed Corporation (NASDAQ:IRMD) by 113.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,774 shares of the medical equipment provider’s stock after buying an additional 12,657 shares during the period. Barclays PLC’s holdings in Iradimed were worth $1,196,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Huntington National Bank grew its holdings in Iradimed by 51.3% during the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 504 shares during the period. Gladius Capital Management LP boosted its position in shares of Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 965 shares in the last quarter. Quantbot Technologies LP grew its stake in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 1,052 shares during the period. SG Americas Securities LLC bought a new stake in Iradimed in the third quarter worth approximately $147,000. Finally, Principal Financial Group Inc. acquired a new position in Iradimed in the third quarter valued at approximately $246,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insider Buying and Selling at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 37.10% of the company’s stock.

Iradimed Stock Down 0.6 %

Shares of IRMD stock opened at $54.67 on Monday. The firm has a 50 day moving average of $53.30 and a 200-day moving average of $48.77. The company has a market cap of $692.67 million, a price-to-earnings ratio of 37.45 and a beta of 0.82. Iradimed Corporation has a 52 week low of $40.18 and a 52 week high of $57.95.

Iradimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s payout ratio is 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.